| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRKAg3 |
| Uniprot No | Q9UGI9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-489aa |
| 氨基酸序列 | MEPGLEHALR RTPSWSSLGG SEHQEMSFLE QENSSSWPSP AVTSSSERIR GKRRAKALRW TRQKSVEEGE PPGQGEGPRS RPAAESTGLE ATFPKTTPLA QADPAGVGTP PTGWDCLPSD CTASAAGSST DDVELATEFP ATEAWECELE GLLEERPALC LSPQAPFPKL GWDDELRKPG AQIYMRFMQE HTCYDAMATS SKLVIFDTML EIKKAFFALV ANGVRAAPLW DSKKQSFVGM LTITDFILVL HRYYRSPLVQ IYEIEQHKIE TWREIYLQGC FKPLVSISPN DSLFEAVYTL IKNRIHRLPV LDPVSGNVLH ILTHKRLLKF LHIFGSLLPR PSFLYRTIQD LGIGTFRDLA VVLETAPILT ALDIFVDRRV SALPVVNECG QVVGLYSRFD VIHLAAQQTY NHLDMSVGEA LRQRTLCLEG VLSCQPHESL GEVIDRIARE QVHRLVLVDE TQHLLGVVSL SDILQALVLS PAGIDALGA |
| 预测分子量 | 54,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRKAG3重组蛋白的3篇示例参考文献(注：文献为虚构示例，仅作格式参考)：
1. **文献名称**: "Recombinant PRKAG3 expression in mammalian cells and its role in AMPK complex activation"
**作者**: Johnson, R.B., et al.
**摘要**: 研究利用HEK293细胞成功表达并纯化重组PRKAG3蛋白，证实其与AMPK α/β亚基形成功能复合物，增强细胞能量应激下的酶活性调节能力。
2. **文献名称**: "Crystal structure analysis of the PRKAG3 subunit and implications for metabolic disease therapeutics"
**作者**: Chen, L., & Tanaka, M.
**摘要**: 通过重组PRKAG3蛋白的晶体结构解析，揭示了其核苷酸结合域的关键位点突变如何影响AMPK活性，为肥胖相关代谢疾病的靶向治疗提供结构基础。
3. **文献名称**: "Functional characterization of PRKAG3 recombinant protein in skeletal muscle glycogen regulation"
**作者**: Martinez, S., et al.
**摘要**: 利用原核系统表达重组PRKAG3蛋白，体外实验证明其通过调控AMPK信号通路，显著影响骨骼肌细胞的糖原合成与分解代谢平衡。
(提示：实际文献需通过PubMed或Google Scholar检索关键词如"PRKAG3 recombinant protein" "AMPK gamma 3"等获取。)
PRKAg3 (protein kinase AMP-activated gamma 3 non-catalytic subunit), also known as PRKAG3. is a regulatory subunit of the AMP-activated protein kinase (AMPK) complex, a central energy sensor critical for maintaining cellular metabolic homeostasis. The AMPK heterotrimer consists of a catalytic α-subunit, a scaffolding β-subunit, and a regulatory γ-subunit. PRKAG3 encodes the γ3 isoform, which is primarily expressed in skeletal muscle and cardiac tissue, distinguishing it from other γ-subunits (γ1. γ2) with broader tissue distribution.
This subunit contains four conserved cystathionine β-synthase (CBS) domains that bind adenosine nucleotides (AMP/ATP/ADP), enabling AMPK to respond to fluctuations in cellular energy status. Elevated AMP/ADP levels promote AMPK activation, stimulating catabolic pathways (e.g., glucose uptake, fatty acid oxidation) while inhibiting anabolic processes. PRKAG3's muscle-specific expression suggests specialized roles in regulating energy metabolism during exercise, muscle contraction, and substrate utilization. Notably, mutations in PRKAG3 are linked to glycogen storage diseases and hypertrophic cardiomyopathy in animal models, highlighting its importance in muscle physiology.
Recombinant PRKAG3 protein is produced using expression systems (e.g., E. coli, mammalian cells) for structural and functional studies. It serves as a tool to investigate AMPK assembly, nucleotide-binding kinetics, and isoform-specific regulatory mechanisms. Researchers utilize it to explore metabolic disorders, muscle diseases, and therapeutic strategies targeting AMPK dysregulation, such as type 2 diabetes, obesity, and cancer. Its application also extends to drug discovery, enabling screening for AMPK modulators. However, challenges remain in understanding tissue-specific interactions and post-translational modifications influencing its activity.
×
